Liraglutida (Saxenda®) é aprovado no Brasil para o tratamento da obesidade

Na última semana foi aprovada pela ANVISA uma nova alternativa para o tratamento da obesidade.

Trata-se do SAXENDA, uma versão nova da liraglutida, que há alguns anos já vem sendo utilizada para o manejo de pacientes com diabetes tipo 2. A diferença está na dosagem. O SAXENDA é aplicado em doses maiores do que a sua versão para diabéticos.

Quando associado a uma mudança de dieta e atividade física, os pacientes com SAXENDA perdem mais peso do que aqueles que não fazem o tratamento medicamentoso. Assim, tem-se mais uma alternativa à disposição para tratar essa doença crônica que é a obesidade. O principal respaldo científico para a aprovaçao. veio no ano passado

Foi publicado em 2015 o estudo SCALE, no New England Journal of Medicine, um dos mais conceituados periódicos médicos do planeta, demonstrando o efeito da liraglutida na redução do peso corporal, conforme resumo em língua inglesa:
“Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon- like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.
METHODS
We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilo- grams divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We ran- domly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight.
RESULTS
At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of −5.6 kg; 95% confi- dence interval, −6.0 to −5.1; P<0.001, with last-observation-carried-forward impu- tation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moder- ate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group.”